

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

-----

FORM 8-K

-----

CURRENT REPORT

Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):  
September 4, 2007

USANA HEALTH SCIENCES, INC.  
(Exact name of registrant as specified in its charter)

Commission File No. 0-21116

Utah	87-0500306
(State or other jurisdiction of incorporation)	(IRS Employer Identification Number)

3838 West Parkway Boulevard  
Salt Lake City, Utah 84120  
(Address of principal executive offices, Zip Code)

Registrant's telephone number, including area code: (801) 954-7100

Former name or former address, if changed since last report: Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to  
simultaneously satisfy the filing obligation of the registrant under any of the  
following provisions:

- Written communications pursuant to Rule 425 under the Securities Act  
(17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act  
(17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the  
Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the  
Exchange Act (17 CFR 240.13e-4(c))

Item 4.01 Changes in Registrant's Certifying Accountant

(b) New independent registered public accounting firm.

On September 4, 2007, the Company appointed PricewaterhouseCoopers LLP  
("PwC") as its new independent registered public accounting firm for the fiscal  
year ending December 29, 2007. The decision to appoint PwC was made and approved  
by the Audit Committee of the Board of Directors.

During the two most recent fiscal years ended December 30, 2006 and  
December 31, 2005, and the subsequent interim period through September 4, 2007,  
the Company has not consulted with PwC regarding: (i) the application of  
accounting principles to a specified transaction, either completed or proposed,  
or the type of audit opinion that might be rendered on the Company's financial  
statements and neither a written report was provided to the Company nor oral  
advice was provided that PwC concluded was an important factor considered by the  
Company in reaching a decision as to the accounting, auditing, or financial  
reporting issue; or (ii) any matter that was either the subject of a  
disagreement, as that term is defined in Item 304(a)(1)(iv) of Regulation S-K

and the related instructions to Item 304 of Regulation S-K, or a reportable event, as that term is defined in Item 304(a)(1)(v) of Regulation S-K.

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

USANA HEALTH SCIENCES, INC.

By: /s/ Gilbert A. Fuller  
Gilbert A. Fuller, Executive VP and CFO

Date: September 5, 2007